Glucagon-like Peptide-1 Receptor Agonists and Risk for Ischemic Optic Neuropathy : A Target Trial Emulation.

What Was Tested

This observational study looks at Glucagon.

To estimate the effect of GLP-1RAs versus sodium-glucose cotransporter-2 inhibitors (SGLT2is) and dipeptidyl peptidase-4 inhibitors (DPP4is) on risk for ION.

Why It Was Studied

Diagnostic codes specifically for NAION were lacking.

Missing data on key clinical factors (such as body mass index and type 2 diabetes duration) may contribute to residual confounding, leaving uncertainty about whether the observed association is causal.

Who Took Part

The abstract describes 10,000 patients taking part.

By PubMed's age tags, the people studied were teenagers, young adults, adults, middle-aged adults and older adults, both men and women.

Patients aged 18 to 65 years with type 2 diabetes initiating a GLP-1RA, an SGLT2i, or a DPP4i.

Analyses adjusted for more than 80 covariates using inverse probability of treatment weights, and 18-month cumulative incidence and risk differences (RDs) per 10 000 patients were estimated.

How the Study Was Run

Observational emulation of a target trial.

Large U.S.-based commercial claims database (January 2017 to December 2022).

The primary outcome was incident ION as a proxy for NAION.

What Was Measured

PubMed files the paper under topics including Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2, Optic Neuropathy, Ischemic, Dipeptidyl-Peptidase IV Inhibitors, Sodium-Glucose Transporter 2 Inhibitors, Hypoglycemic Agents and Risk Factors.

What This Means in Plain Language

This is an observational study of Glucagon in 10,000 patients.

With several hundred people or more, it is a fairly large study for this kind of research.

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2026 (Annals of internal medicine), a journal based in United States.

More context: the Glucagon compound page, all human trials.